Despite a challenging quarter, OPKO Health Inc (OPK) focuses on core strengths and strategic partnerships to drive future profitability.

OPKO Health, Inc. OPK delivered a loss per share of 4 cents in the fourth quarter of 2025, against an earnings per share of a ...

OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its ...

MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces ...

OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial ...

Phillip Frost, Chairman and Chief Executive Officer, will provide opening remarks. Elias Zerhouni, Vice Chairman and ...

For the quarter ended December 2025, OPKO Health (OPK) reported revenue of $148.5 million, down 19.1% over the same period last year. EPS came in at -$0.04, compared to $0.01 in the year-ago quarter.

OPKO Health (OPK) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.01 per share a year ago. These figures are ...

An interdisciplinary team of Boston College researchers to explore how social norms can be leveraged to promote virtuous behavior Professor of Psychology and Neuroscience Liane Young, whose research ...

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals.

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals.